12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Other News

Invitae, Myriad Genetics diagnostic news

Invitae filed a suit in the U.S. District Court for the Northern District of California seeking declaratory judgment that Myriad's breast cancer 1 early onset (BRCA1) and BRCA2 patents are invalid and not infringed by Invitae's assays. Invitae...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >